Loading...

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

9989.HKHKSE
Healthcare
Drug Manufacturers - Specialty & Generic
HK$5.34
HK$0.010(0.19%)

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. 9989.HK Peers

See (9989.HK) competitors and their performances in Stock Market.

Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
9989.HKHK$5.34+0.19%17.3B11.13HK$0.48+39.93%
3692.HKHK$30.25+1.68%179.9B37.81HK$0.80N/A
2196.HKHK$16.94+0.36%68.5B14.12HK$1.20+1.77%
0874.HKHK$17.58+1.03%44.2B9.71HK$1.81+5.00%
3320.HKHK$5.26+2.73%33B9.07HK$0.58+2.79%
1513.HKHK$29.80+1.53%32.8B11.73HK$2.52+4.02%
0512.HKHK$8.95+2.64%31.3B12.79HK$0.70+2.91%
0867.HKHK$12.20+1.67%29.5B16.71HK$0.73+2.39%
3933.HKHK$15.24+1.46%27.7B9.53HK$1.60+1.16%
0013.HKHK$24.90+5.73%21.7B80.32HK$0.31N/A
Showing 1 to 10 of 42 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

9989.HK vs 3692.HK Comparison

9989.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 9989.HK stands at 17.3B. In comparison, 3692.HK has a market cap of 179.9B. Regarding current trading prices, 9989.HK is priced at HK$5.34, while 3692.HK trades at HK$30.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

9989.HK currently has a P/E ratio of 11.13, whereas 3692.HK's P/E ratio is 37.81. In terms of profitability, 9989.HK's ROE is +0.05%, compared to 3692.HK's ROE of +0.15%. Regarding short-term risk, 9989.HK is more volatile compared to 3692.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 9989.HK.

Stock Price Comparison

Loading...

Frequently Asked Questions

;